Skip to main content
SpringerLink
Log in

Treatment of relapse after allogeneic bone marrow transplantation

  • Chapter
Molecular Genetics and Therapy of Leukemia

Part of the book series: Cancer Treatment and Research ((CTAR,volume 84))

Abstract

Disease relapse after allogeneic bone marrow transplantation (BMT) for hematologic malignancies remains the single most important cause of treatment failure [1–4]. Improvements in supportive care, prophylaxis of graft versus host disease (GVHD), and treatment of infectious complications have resulted in a decrease in transplant-related mortality during the years. However, modifications in the conditioning regimen and other strategies to prevent relapse have failed, and the relapse rate after allogeneic transplant has remained constant throughout the years [5,6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bortin M, Horowitz M, Rimm A (1992). Increasing utilization of allogeneic bone marrow transplantation: results of the 1988–1990 survey. Ann Intern Med 116:505.

    PubMed  CAS  Google Scholar 

  2. Champlin R, McGlave P (1994). Allogeneic bone marrow transplantation for chronic myelogenous leukemia. In Forman S, Blume K, Thomas E (eds), Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, pp. 595–606.

    Google Scholar 

  3. Long G, Blume K (1994). Allogeneic bone marrow transplantation for acute myeloid leukemia. In Forman S, Blume K, Thomas E (eds), Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, pp. 607–618.

    Google Scholar 

  4. Chao N, Forman S (1994). Allogeneic bone marrow transplantation for acute lymphoblastic leukemia. In Forman S, Blume K, Thomas E (eds), Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, pp. 618–628.

    Google Scholar 

  5. Bortin M, Horowitz M, Gale R, Barrett J, Champlin R, Dicke K, Gluckman E, Kolb H, Marmont A, Mrsic M, Sobocinski K, Weiner R, Rimm A (1992). Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA 268:607.

    Article  PubMed  CAS  Google Scholar 

  6. Aurer I, Gale RP (1991) Are new conditioning regimens for transplants in acute myelogenous leukemia better? Bone Marrow Transplant 7:255–261.

    PubMed  CAS  Google Scholar 

  7. Frassoni F, Barrett J, Granena A, Ernst P, Garthon G, Kolb H, Prentice H, Vernant J, Zwaan E, Gratwohl A (1988). Relapse after allogeneic bone marrow transplantation for acute leukemia. A survey of the EBMTR of 117 cases. Br J Hematol 70:317.

    Article  CAS  Google Scholar 

  8. Mortimer J, Binder M, Schulman S, Appelbaum F, Buckner C, Cliff R, Sanders J, Storb R, Thomas E (1989). Relapse of acute leukemia after marrow transplantation. Natural history and results of subsequent therapy. J Clin Oncol 7:50.

    PubMed  CAS  Google Scholar 

  9. Arcese W, Goldman J, Arcangelo E, Schattenberg A, Nardi A, Apperley J, Frassoni F, Aversa F, Prentice H, Ljungman P, Ferrant A, Marosis C, Sayer H, Niederwieser D, Arnold R, Bandini G, Carreras E, Parker A, Frappaz D, Mandelli F, Gratwohl A, for the Chronic Leukemia Working Party of the European Bone Marrow Transplantation Group (1993). Outcome of patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 82:3211.

    PubMed  CAS  Google Scholar 

  10. Arthur C, Apperley J, Guo A, Rassool F, Gao L, Goldman J (1988). Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase. Blood 71:1179.

    PubMed  CAS  Google Scholar 

  11. Hughes T, Economou K, Mackinnon S, Ulitos M, Arthur C, Guo A, Rassool F, Apperley J, Hows J, Goldman J (1989). Slow evolution of chronic myeloid leukemia relapsing after bone marrow transplantation with T-cell depleted donor marrow. Br J Hematol 73:462.

    Article  Google Scholar 

  12. Odom L, Githers J, Morse H, Sharna B, August c, Humbert J, Peakman D, Rosnak S, Johnson F (1978). Remission of relapsed leukemia during a graft-versus-host reaction. A graft-versus-leukemia reaction in man? Lancet 2:537.

    Article  PubMed  CAS  Google Scholar 

  13. Higano C, Brixey M, Bryant E, Durman D, Doney K, Sullivan K, Singer J (1990). Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marror transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 50:175.

    Article  PubMed  CAS  Google Scholar 

  14. Collins R, Rogers Z, Bennett M, Kumar V, Nikein A, Fay J (1992). Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppresion. Bone Marrow Transplant 10:391.

    PubMed  Google Scholar 

  15. Flowers M, Clift R, Schoch G, Sullivan K, Martin P (1994). Discontinuation of cyclosporine to induce a graft-versus-leukemia effect in patients with cytogenetic relapse after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood 84 (Suppl 1):540a.

    Google Scholar 

  16. Bostrom B, Woods W, Nesbit M, Krivit W, Kersey J, Weisdorf D, Haake R, Goldman A, Ramsey N (1987). Succesful reinduction of patients with acute lymphoblastic leukemia who relapse following bone marrow transplantation. J Clin Oncol 5:376.

    PubMed  CAS  Google Scholar 

  17. Barrett A, Tew C, Joshi R (1985). How should acute lymphoblastic leukemia relapsing after bone-marrow transplantation be treated? Lancet 1:1188.

    Article  PubMed  CAS  Google Scholar 

  18. Barrett A, Joshi R, kencha J, Phillips R, Ashford R, Shaw P, Hugh-Jones K, Hobbs J (1986). Prediction and prevention of relapse of acute lymphoblastic leukemia after bone marrow transplantation. Br J Haematol 64:179.

    Article  PubMed  CAS  Google Scholar 

  19. Doney K, Fisher L, Appelbaum F, Buckner C, Storb R, Singer J, Fefer A, Anasetti C, Beatty P, Bensinger W, Clift R, Hansen J, Hill R, Loughran T, Martin P, Petersen F, Sanders J, Sullivan K, Stewart P, Weiden P, Witherspoon R, Thomas E (1991). Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation: multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse free survival. Bone Marrow Transplant 7:453.

    PubMed  CAS  Google Scholar 

  20. Chak L, Sapozink M, Cox R (1983). Extramedullary lesions in non-lymphocytic leukemia results of radiation therapy. Int J Radiat Oncol Biol Phys 9:1173.

    Article  PubMed  CAS  Google Scholar 

  21. Bowman W, Aur R, Hustu H, Rivera G (1984). Isolated testicular relapse in acute lymphocytic leukemia of childhood: categories and influence on survival. J Clin Oncol 2:924.

    PubMed  CAS  Google Scholar 

  22. Wright S, Thomas E, Buckner C, Clift R, Fefer A, Neiman P, Storb R (1976). Experience with second marrow transplants. Exp Hematol 4:221.

    PubMed  CAS  Google Scholar 

  23. Champlin R, Ho W, Lenarsky C, Mitsuyasu R, Feig S, Gale R (1985). Succesful second bone marrow transplantation for AML or ALL. Transplant Proc 17:496.

    Google Scholar 

  24. Sanders J, Buckner C, Clift R, Fefer A, McGuffin R, Storb R, Appelbaum F, Bensinger W, Beatty P, Doney K, Durnam D, Martin P, Sullivan K, Stewart P, Witherspoon R, Thomas E (1988). Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. Bone Marrow Transplant 3:11.

    PubMed  CAS  Google Scholar 

  25. Radich J, Sanders J, Buckner C, Martin P, Petersen F, Bensinger W, McDonald G, Mori M, Scoch G, Hansen J (1993). Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total body irradiation containing regimens. J Clin Oncol 11:304.

    PubMed  CAS  Google Scholar 

  26. Stern L, Landan M, Feig S, Gajewski J (1992). Outcome of second bone marrow transplants. Blood 80:334a.

    Google Scholar 

  27. Wagner J, Vogelsang G, Zehnbauer B, Griffen C, Shan N, Santos G (1992). Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy. Bone Marrow Transplant 9:205.

    PubMed  CAS  Google Scholar 

  28. Barrett A, Locatelfi F, Treleaven J, Gratwohl A, Szydlo R, Zwaan F (1991). Second transplants for leukemic relapse after bone marrow transplantation: high early mortality but favorable effect of chronic GVHD on continued remission. Br J Hematol 78:561.

    Article  Google Scholar 

  29. Mrsic M, Horowitz M, Atkinson K, Biggs J, Champlin R, Ehninger G, Gajewski J, Gale R, Herzig R, Prentice H, Rozman C, Sobocinski K, Speck B, Bortin M (1992). Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 9:269.

    PubMed  CAS  Google Scholar 

  30. Blume K, Forman S (1987). High dose busulfan/etoposide as a preparatory regimen for second bone marrow transplants in hematologic malignancies. Blut 55:49.

    Article  PubMed  CAS  Google Scholar 

  31. Atkinson K, Biggs J, Concannon A, Dodds A, Dale B, Norman J (1986). Second marrow transplants for recurrence of hematological malignancy. Bone Marrow Transplant 1:159.

    PubMed  CAS  Google Scholar 

  32. Nemunaitis J, Albo V, Zeigler Z, Shadduck R, Rosenfeld C (1993). Reduction of allogeneic transplant morbidity by combining peripheral blood and bone marrow progenitor cells. Leuk Lymphoma 10:405.

    Article  PubMed  CAS  Google Scholar 

  33. Russell N, Hunter A, Rogers S, Hanley J, Anderson D (1993). Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 341:1482.

    Article  PubMed  CAS  Google Scholar 

  34. Korbling M, Przepiorka D, Engel H, van Besien K, Giralt S, Anderson B, Huh Y, Deisseroth A, Andreeff M, Champlin R (1994). Allogeneic blood stem cell transplantation (allo-pbsct) in 9 patients with refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 84 (Suppl 1):396a.

    Google Scholar 

  35. Giralt S, Escudier S, Kantarjian H, Deisseroth A, Freireich E, Andersson B, O’Brien S, Andreef M, Fisher H, Cork A, Hirsch-Ginsbery C, Trujillo J, Stass S, Champlin R (1993). Treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. Preliminary observations. N Engl J Med 329:357.

    Article  Google Scholar 

  36. Giralt S, Hester J, Talpaz M, Kantarjian H, Van Besien K, Andersson B, Chan K, Gajewski J, Mehra R, Przepiorka D, Deisseroth A, Champlin R (1994). Cytokine therapy for patients relapsing after allogeneic bone marrow transplantation. J Cell Biochem (Suppl 18B):88a.

    Google Scholar 

  37. Tafuri A, Andreeff M (1990). Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4:826.

    PubMed  CAS  Google Scholar 

  38. Baron S, Tyring S, Fleischmann W, Coppenhaver D, Niesen D, Kumpel G, Stanton J, Hughes T (1991). The interferons. Mechanism of action and clinical applications. JAMA 266:1375.

    Article  PubMed  CAS  Google Scholar 

  39. Talpaz M, Kantarjian H, Kurzroch R, Trujillo J, Gutterman J (1991). Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114:532.

    PubMed  CAS  Google Scholar 

  40. Arcese W, Mauro F, Alimena G, Lo Coco F, De Cuia M, Screnci M, Iori A, Montefusco E, Mandelli F (1991). Interferon therapy for Ph positive CML patients relapsing after T-cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 5:309.

    Google Scholar 

  41. Higano C, Raskind W, Singer J (1992). Use of α-interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 80:1437.

    PubMed  CAS  Google Scholar 

  42. Rosenberg S, Grimm E, McGrogan M, Doyle M, Kawasaki E, Koths K, Marks D (1984). Biological activity of recombinant human interleukin-2. Science 223:1412.

    Article  PubMed  CAS  Google Scholar 

  43. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H (1986). Cytotoxicity of interleukin-2 activated lymphocytes for leukemia and lymphoma cells. Blood 68:938.

    PubMed  CAS  Google Scholar 

  44. Maraninchi D, Blaise D, Viens P, Brandely M, Olive D, Lopez M, Sainty D, Marit G, Stoppa A, Reiffers J, Gratecos N, Bertau-perez P, Mannoni P, Mawas C, Hercend T, Sebahoun G, Carcassonne Y (1991). High dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 78:218.

    Google Scholar 

  45. Foa R, Meloni G, Tosti S, Novarino A, Fern S, Gavosta F (1991). Treatment of acute myelogenous leukemia patients with recombinant interleukin-2: a pilot study. Br J Hematol 77:491.

    Article  CAS  Google Scholar 

  46. Kolb H, Mittermuller J, Clemm C, Holler E, Ledrerose G, Brehm G, Heim M, Wilmanns W (1990). Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462.

    PubMed  CAS  Google Scholar 

  47. Frassoni F, Fagioli F, Sessarego M, Figari F, Valbonesi M, Bacigalupo A (1992). The effect of donor leucocyte infusion in patients with leukemia following allogeneic bone marrow transplantation. Exp Hematol 20:712a.

    Google Scholar 

  48. Porter D, Roth M, McGarigle C, Ferrara J, Antin J (1994). Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100.

    Article  PubMed  CAS  Google Scholar 

  49. Drobyski W, Keever C, Roth M, Koethe S, Hanson G, McFadden P, Gottschal J, Ash R, Van Tuinen P, Horowitz M, Flomenberg N (1993). Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82:2310.

    PubMed  CAS  Google Scholar 

  50. Szer J, Grigg A, Phillips G, Sheridan W (1993). Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukemia following allogeneic BMT. Bone Marrow Transplant 11:109.

    PubMed  CAS  Google Scholar 

  51. Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, Wyss M, Jeannet M, Chapuis B, Roosnek E (1993). Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 12:125.

    PubMed  CAS  Google Scholar 

  52. van Rhee F, Lin F, Cullis J, Spencer A, Cross N, Chase A, Garicochea B, Bungey J, Barrett J, Goldman J (1994). Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377.

    PubMed  Google Scholar 

  53. Bar B, Schattenberg A, Mensink E, Geurts Van Kessel A, Smetsers T, Knops G, Linders E, De Witte T (1993). Donor leukocyte infusions for chronic myelogenous leukemia after allogeneic bone marrow transplantation. J Clin Oncol 11:513.

    PubMed  CAS  Google Scholar 

  54. Hertenstein B, Wiesneth M, Novotny J, Bunjes D, Stefanic M, Heinze B, Hübner G, Heimpel H, Arnold R (1993). Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 56:1114–1118.

    Article  PubMed  CAS  Google Scholar 

  55. Kolb H, de Witte T, Mittermuller J, Hertenstein B, Goldman J, Ljungman P, Verdonck L, Holler E, Thalmeier K, Bartram C for the EBMT Chronic Leukemia Working Party (1993). Graft-versus-leukemia effect of donor buffy coat transfusions on recurrent leukemia after marrow transplantation. Blood 82 (Suppl 1):214a.

    Google Scholar 

  56. Antin J (1993). Graft-versus-leukemia: no longer an epiphenomenon. Blood 82:2273.

    PubMed  CAS  Google Scholar 

  57. Faber L, van Luxemberg-Heijs S, Willemze R, Falkenburg J (1992). Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 176:1283–1289.

    Article  PubMed  CAS  Google Scholar 

  58. Sosman J, Oettel K, Smith S, Hank J, Fisch P, Sondel P (1990). Specific recognition of human leukemic cells by allogeneic T-cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated non leukemic cells. Blood 75:2005–2016.

    PubMed  CAS  Google Scholar 

  59. Jiang Y, Kanfer E, MacDonald D, Cullis J, Goldman J, Barrett A (1991). Graft versus leukemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukemia cells. Bone Marrow Transplant 8:253–258.

    PubMed  CAS  Google Scholar 

  60. Jiang Y, Cullis J, Kanfer E, Goldman J, Barrett A (1993). T cell and NK cell mediated graft-versus-leukemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 11:133–138.

    PubMed  CAS  Google Scholar 

  61. Hercend T, Takvorian T, Nowill A, et al. (1986). Characterization of natural killer cells with anti-leukemia activity following allogeneic bone marrow transplantation. Blood 67:301–305.

    Google Scholar 

  62. Hoffmann T, Theobald M, Bunjes D, Weiss M, Heimpel H, Heit W (1993). Frequency of bone marrow T-cells responding to HLA-identical non-leukemic and leukemic stimulator cells. Bone Marrow Transplant 12:1.

    PubMed  CAS  Google Scholar 

  63. Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, Boulad F, Castro-Malaspina H, Childs B, Gillio A, Kernan N, Small T, Young J, O’Reilly R (1994). Adoptive immunotherapy using escalating doses of donor leukocytes for relapsed chronic myeloid leukemia following allogeneic bone marrow transplantation. Blood 84 (Suppl 1):538a.

    Google Scholar 

  64. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondón, Guo J, Lee M, Gajewski J, Talpaz M, kantarjian H, Fischer H, Deisseroth A, Champlin R (1994). CD8+ depleted donor lymphocyte infusion for relapsed chronic myelogenous leukemia (CML) after allogeneic bone marrow transplantation (BMT): graft vs leukemia without graft vs host disease (GVHD). Blood 84 (Suppl 1):538a.

    Google Scholar 

  65. Collins R, Wolff S, List A, Christiansen N, Pineiro L, Greer J, Goodman S, Dalton W, Gonzalez G, Herzig G, Phillips G, Fay J (1994). Prospective multicenter trial of donor buffy coat infusion for relapsed hematologic malignancy post allogeneic bone marrow transplantation (BMT). Blood 84 (Suppl 1):333a.

    Google Scholar 

  66. Verfaillie C, Weisdorf D, McGlave P, Vercellotti G, Enright H, Burns L, Miller J (1994). High dose mononuclear cell infusion in post transplant relapsed AML/MDS. Blood 84 (Suppl 1):333a.

    Google Scholar 

  67. Slavin S, Nagler A (1991). New developments in bone marrow transplantation. Curr Opin Oncol 3:254.

    Article  PubMed  CAS  Google Scholar 

  68. Klingemann H, Phillips G (1991). Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 8:73.

    PubMed  CAS  Google Scholar 

  69. Slavin S, Weiss L, Ackerstein A, Vourka-Karussis U, Morecki S, Or R, Nagler A, Kapelushnik J, Delukina M, Drakos P, Naparstek E (1991). Prevention and treatment of relapse by bone marrow transplantation. Bone Marrow Transplant 7 (Suppl 1):54.

    Google Scholar 

  70. Appelbaum F, Matthews D, Eary J, Badger C, Kellog M, Preis O, Martin P, Fisher D, Nelp W, Thomas E (1992). The use of radiolabeled anti CD-33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 54:829.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Sergio A. Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koen Van Besien
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Hematology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Doulevard, Box 55, Houston, TX, 77030, USA

    Emil J. Freireich M.D.

  2. Department of Hematology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 61, Houston, TX, 77030, USA

    Hagop Kantarjian M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers, Boston

About this chapter

Cite this chapter

Giralt, S.A., Van Besien, K. (1996). Treatment of relapse after allogeneic bone marrow transplantation. In: Freireich, E.J., Kantarjian, H. (eds) Molecular Genetics and Therapy of Leukemia. Cancer Treatment and Research, vol 84. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1261-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1261-1_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8537-3

  • Online ISBN: 978-1-4613-1261-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation